Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)
27.05
-0.41 (-1.49%)
Nov 13, 2026, 3:00 PM CST
SHA:600976 Revenue
Jianmin Pharmaceutical Group had revenue of 686.12M CNY in the quarter ending September 30, 2026, a decrease of -8.19%. This brings the company's total for the last twelve months to 3.12B, down -1.90% year-over-year. In the year 2025, Jianmin Pharmaceutical Group had annual revenue of 3.37B, down -3.85%. That makes Jianmin Pharmaceutical Group the 11,663rd largest company in the world by revenue and 1,984th in China.
Revenue (ttm)
3.12B
Revenue Growth
-1.90%
P/S Ratio
1.33
Revenue / Employee
1.38M
Employees
2,257
Market Cap
4.15B
Revenue by Segment
- Pharmaceutical Production and Sales 3.80B 73.5%
- Commercial 1.37B 26.5%
Fiscal year ended Dec 31, 2025 See the full SHA:600976 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.37B | -135.08M | -3.85% |
| Dec 31, 2024 | 3.50B | -708.17M | -16.81% |
| Dec 31, 2023 | 4.21B | 572.35M | 15.72% |
| Dec 31, 2022 | 3.64B | 341.37M | 10.35% |
| Dec 31, 2021 | 3.30B | 843.43M | 34.34% |
| Jan 1, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Luoxin Pharmaceuticals Group Stock | 2.23B |
| Hunan Fangsheng Pharmaceutical | 1.88B |
| Fuan Pharmaceutical (Group) | 1.65B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.64B |
| Shandong Wit Dyne Health | 1.51B |
| Hunan Hansen Pharmaceutical | 1.01B |
| Zhongzhu Healthcare Holding Co.,Ltd | 535.62M |
| Hubei Biocause Heilen Pharmaceutical | 488.84M |